Greenwich Lifesciences Stock Performance
| GLSI Stock | USD 10.91 0.26 2.44% |
Greenwich Lifesciences has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 2.0, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Greenwich Lifesciences will likely underperform. Greenwich Lifesciences right now retains a risk of 3.65%. Please check out Greenwich Lifesciences jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to decide if Greenwich Lifesciences will be following its current trending patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Greenwich Lifesciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating basic indicators, Greenwich Lifesciences may actually be approaching a critical reversion point that can send shares even higher in November 2025. ...more
Actual Historical Performance (%)
One Day Return 2.44 | Five Day Return 5.11 | Year To Date Return (7.07) | Ten Year Return 118.2 | All Time Return 118.2 |
1 | Greenwich LifeSciences to Release Earnings on Wednesday | 08/12/2025 |
2 | Can trapped investors hope for a rebound in Greenwich LifeSciences Inc. - Market Performance Report Free Fast Entry Momentum Trade Alerts - Newser | 08/27/2025 |
3 | Published on 2025-09-05 224700 - | 09/05/2025 |
4 | Greenwich LifeSciences GLSI-100 Granted US FDA Fast Track Designation | 09/10/2025 |
5 | Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland | 09/18/2025 |
6 | Greenwich LifeSciences, Inc. CEO Snehal Patels holdings dropped 12 percent in value as a result of the recent pullback | 09/29/2025 |
7 | Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium | 10/02/2025 |
| Begin Period Cash Flow | 7 M | |
| Free Cash Flow | -7.3 M |
Greenwich | Build AI portfolio with Greenwich Stock |
Greenwich Lifesciences Relative Risk vs. Return Landscape
If you would invest 1,007 in Greenwich Lifesciences on July 7, 2025 and sell it today you would earn a total of 84.00 from holding Greenwich Lifesciences or generate 8.34% return on investment over 90 days. Greenwich Lifesciences is currently generating 0.188% in daily expected returns and assumes 3.6458% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Greenwich, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Greenwich Lifesciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Greenwich Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Greenwich Lifesciences, and traders can use it to determine the average amount a Greenwich Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0516
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GLSI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.65 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Greenwich Lifesciences is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Greenwich Lifesciences by adding it to a well-diversified portfolio.
Greenwich Lifesciences Fundamentals Growth
Greenwich Stock prices reflect investors' perceptions of the future prospects and financial health of Greenwich Lifesciences, and Greenwich Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Greenwich Stock performance.
| Return On Equity | -4.92 | ||||
| Return On Asset | -2.19 | ||||
| Current Valuation | 142.04 M | ||||
| Shares Outstanding | 13.63 M | ||||
| Price To Book | 100.84 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.79 M) | ||||
| Cash And Equivalents | 15.64 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.56 M | ||||
| Current Ratio | 65.74 X | ||||
| Book Value Per Share | 0.11 X | ||||
| Cash Flow From Operations | (7.27 M) | ||||
| Earnings Per Share | (1.37) X | ||||
| Market Capitalization | 148.71 M | ||||
| Total Asset | 4.09 M | ||||
| Retained Earnings | (66.15 M) | ||||
| Working Capital | 2.53 M | ||||
About Greenwich Lifesciences Performance
By evaluating Greenwich Lifesciences' fundamental ratios, stakeholders can gain valuable insights into Greenwich Lifesciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Greenwich Lifesciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Greenwich Lifesciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.86) | (4.05) | |
| Return On Capital Employed | (6.32) | (6.00) | |
| Return On Assets | (3.86) | (4.05) | |
| Return On Equity | (6.23) | (5.92) |
Things to note about Greenwich Lifesciences performance evaluation
Checking the ongoing alerts about Greenwich Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Greenwich Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Greenwich Lifesciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Greenwich Lifesciences currently holds about 15.64 M in cash with (7.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium |
- Analyzing Greenwich Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Greenwich Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining Greenwich Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Greenwich Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Greenwich Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Greenwich Lifesciences' stock. These opinions can provide insight into Greenwich Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Greenwich Stock analysis
When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |